WEKO3
アイテム
Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations
http://hdl.handle.net/10069/37043
http://hdl.handle.net/10069/370434fe78e31-4e99-4bf8-bc6c-e0fe887c257a
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学位論文 / Thesis or Dissertation(1) | |||||||
---|---|---|---|---|---|---|---|---|
公開日 | 2017-02-06 | |||||||
タイトル | ||||||||
言語 | en | |||||||
タイトル | Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations | |||||||
言語 | ||||||||
言語 | eng | |||||||
キーワード | ||||||||
主題Scheme | Other | |||||||
主題 | Chemotherapy | |||||||
キーワード | ||||||||
主題Scheme | Other | |||||||
主題 | EGFR mutations | |||||||
キーワード | ||||||||
主題Scheme | Other | |||||||
主題 | Elimination half-life | |||||||
キーワード | ||||||||
主題Scheme | Other | |||||||
主題 | Gefitinib | |||||||
キーワード | ||||||||
主題Scheme | Other | |||||||
主題 | Non-small cell lung cancer | |||||||
キーワード | ||||||||
主題Scheme | Other | |||||||
主題 | Pharmacokinetics | |||||||
資源タイプ | ||||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||||
資源タイプ | doctoral thesis | |||||||
アクセス権 | ||||||||
アクセス権 | open access | |||||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||
著者 |
溝口, 孝輔
× 溝口, 孝輔
|
|||||||
著者別名 | ||||||||
姓名 | Mizoguchi, Kosuke | |||||||
抄録 | ||||||||
内容記述タイプ | Abstract | |||||||
内容記述 | Purpose: The relationship between plasma concentration and antitumor activity of gefitinib was assessed in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Patients and methods: Plasma trough levels of gefitinib were measured on days 2 (D2) and 8 (D8) by high-performance liquid chromatography in 31 patients. Plasma concentrations of gefitinib were also measured 10 h after the first administration in 21 of these patients to calculate the elimination half-life of gefitinib. Results: The median trough levels were: 197 ng/ml 10 h from the first administration of gefitinib; 113 ng/ml on D2; and 358 ng/ml on D8. The median D8/D2 ratio was 2.709, and the median elimination half-life was 15.7 h. The median progression-free survival (PFS) was 273 days, and the median overall survival (OS) was 933 days. A high D8/D2 ratio was significantly correlated with better PFS, though the plasma trough levels on D2 and D8 were not significantly related to PFS. The elimination half-life was not a significant factor for PFS, but it was significantly correlated with high-grade adverse events. Pharmacokinetic parameters were not significantly correlated with OS. Conclusions: A high D8/D2 ratio, but not elimination half-life, might be a predictor of better PFS in patients with NSCLC harboring EGFR mutations treated with gefitinib. On the other hand, long elimination half-life was related to high-grade adverse events in these patients. |
|||||||
内容記述 | ||||||||
内容記述タイプ | Other | |||||||
内容記述 | 長崎大学学位論文 学位記番号:博(医歯薬)甲第914号 学位授与年月日:平成29年2月1日 | |||||||
書誌情報 |
Cancer Chemotherapy and Pharmacology 巻 78, 号 2, p. 377-382, 発行日 2017-02-01 |
|||||||
ISSN | ||||||||
収録物識別子タイプ | ISSN | |||||||
収録物識別子 | 03445704 | |||||||
DOI | ||||||||
識別子タイプ | DOI | |||||||
関連識別子 | 10.1007/s00280-016-3097-4 | |||||||
権利 | ||||||||
権利情報 | c Springer-Verlag Berlin Heidelberg 2016 | |||||||
権利 | ||||||||
権利情報 | The final publication is available at link.springer.com | |||||||
著者版フラグ | ||||||||
出版タイプ | VoR | |||||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||
その他のタイトル | ||||||||
その他のタイトル | ゲフィチニブの薬物動態パラメーターと無増悪生存期間・有害事象との相関 | |||||||
出版者 | ||||||||
出版者 | Springer | |||||||
学位名 | ||||||||
学位名 | 博士(医学) | |||||||
学位授与機関 | ||||||||
学位授与機関識別子Scheme | kakenhi | |||||||
学位授与機関識別子 | 17301 | |||||||
学位授与機関名 | Nagasaki University (長崎大学) | |||||||
学位授与年月日 | ||||||||
学位授与年月日 | 2017-02-01 | |||||||
学位授与番号 | ||||||||
学位授与番号 | 甲医歯薬第914号 | |||||||
学位の種類 | ||||||||
課程博士 | ||||||||
引用 | ||||||||
内容記述タイプ | Other | |||||||
内容記述 | Nagasaki University (長崎大学), 博士(医学) (2017-02-01) |